LUCD Profile
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company specializing in the detection and management of gastroesophageal reflux disease (GERD), a condition linked to an elevated risk of esophageal cancer, specifically esophageal adenocarcinoma. The company's primary focus is on providing diagnostic solutions for patients suffering from chronic heartburn, acid reflux, or related conditions, which can potentially progress to esophageal precancer and cancer.
The company’s flagship product, EsoGuard, is a laboratory-developed test designed to analyze esophageal DNA to identify precancerous changes at an early stage. This test aims to enable early intervention and improve patient outcomes by detecting potential esophageal cancer risks before they develop into more severe conditions. Complementing EsoGuard is EsoCheck, an innovative device used for collecting esophageal cell samples, which enhances the accuracy and convenience of diagnostic testing.
Lucid Diagnostics operates with a clear focus on advancing early detection technologies to address significant unmet needs in the management of esophageal diseases. By leveraging its proprietary diagnostic tools, the company aims to transform the approach to GERD and esophageal cancer detection, providing healthcare professionals with critical information to guide treatment decisions and improve patient care.
Incorporated in 2018 and headquartered in New York, Lucid Diagnostics Inc. is a wholly owned subsidiary of PAVmed Inc. The company’s strategic initiatives and product offerings reflect its commitment to enhancing diagnostic capabilities and patient outcomes in the field of gastroenterology. With a strong focus on innovation and clinical utility, Lucid Diagnostics is positioned to play a pivotal role in the future of esophageal disease management.
|
